

Meet The Professor: Optimizing the Management of Hepatobiliary Cancers —
Part 1 of a 2-Part Series

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. Which of the following outcomes was reported from the Phase III HIMALAYA trial investigating the efficacy of durvalumab with or without tremelimumab versus sorafenib for unresectable liver cancer?**
 - Median overall survival (OS) was not met with any regimen
 - Durvalumab with tremelimumab improved OS compared to sorafenib**
 - Durvalumab with tremelimumab did not improve OS compared to sorafenib
 - Durvalumab alone improved OS compared to durvalumab with tremelimumab
- 2. Which of the following selective pan-FGFR inhibitors is being evaluated for patients with unresectable or metastatic intrahepatic cholangiocarcinoma and an FGFR2 fusion in the Phase II FOENIX-CCA2 study?**
 - Erdafitinib
 - Pemigatinib
 - Infigratinib
 - Futibatinib**
- 3. The Phase III ClarIDHy trial demonstrated which of the following outcomes for patients with advanced cholangiocarcinoma and an IDH1 mutation?**
 - A statistically significant improvement in progression-free survival (PFS) with ivosidenib compared to placebo**
 - A statistically significant improvement in PFS with enasidenib compared to placebo
 - A statistically nonsignificant improvement in PFS with ivosidenib compared to placebo
 - A statistically nonsignificant improvement in PFS with enasidenib compared to placebo
- 4. Which of the following best describes the specific mechanism of action of the novel agent zanidatamab for HER2-expressing biliary tract cancers?**
 - Binds to the ECD2 domain of HER2
 - Binds to the ECD4 domain of HER2
 - Binds to ECD2 and ECD4 on HER2**
 - Binds to HER2 and HER3
- 5. The Phase II HERB trial demonstrated promising clinical activity with which of the following agents for HER2-positive or HER2-low biliary tract cancer?**
 - Zanidatamab
 - Trastuzumab deruxtecan**
 - Datopotamab deruxtecan
 - Trastuzumab with pertuzumab